Evidence map›Paper›PMID 39180255›Full record

ArticleJournal of neurochemistry2025

HSP110 is a modulator of amyloid beta (Aβ) aggregation and proteotoxicity.

Sabrina Montresor, Maria Lucia Pigazzini, Sudarson Baskaran, Mira Sleiman, Govinda Adhikari, Lukas Basilicata, Luca Secker, Natascha Jacob, Yara Ehlert, Anushree Kelkar and 4 more

Abstract read
In one paragraph

Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Chaperone-mediated remodelling of mutant huntingtin.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026
    Review
  2. Review
  3. Article
  4. Toxic mechanisms of amyloid oligomers and therapeutic strategies.Protein science : a publication of the Protein Society · 2026
    Review
  5. Recent insights into HSP70: proteostasis and beyond.Frontiers in molecular biosciences · 2026
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sabrina MontresorDepartment of Cell Biology, University of Bremen, Bremen, Germany.ORCID 0009-0006-7218-5640
Maria Lucia PigazziniLeibniz Institute for Molecular Pharmacology, Berlin, Germany.
Sudarson BaskaranLeibniz Institute on Aging-Fritz-Lipmann-Institute, Jena, Germany.
Mira SleimanDepartment of Cell Biology, University of Bremen, Bremen, Germany.
Govinda AdhikariLeibniz Institute on Aging-Fritz-Lipmann-Institute, Jena, Germany.
Lukas BasilicataDepartment of Cell Biology, University of Bremen, Bremen, Germany.
Luca SeckerDepartment of Cell Biology, University of Bremen, Bremen, Germany.
Natascha JacobDepartment of Cell Biology, University of Bremen, Bremen, Germany.
Yara EhlertDepartment of Cell Biology, University of Bremen, Bremen, Germany.
Anushree KelkarDepartment of Cell Biology, University of Bremen, Bremen, Germany.
Gurleen Kaur KalsiDepartment of Cell Biology, University of Bremen, Bremen, Germany.
Niraj KulkarniDepartment of Cell Biology, University of Bremen, Bremen, Germany.
Paul SpellerbergDepartment of Cell Biology, University of Bremen, Bremen, Germany.ORCID 0009-0003-9082-1274
Janine KirsteinLeibniz Institute on Aging-Fritz-Lipmann-Institute, Jena, Germany.ORCID 0000-0003-4990-2497

Funding

Deutsche Forschungsgemeinschaft KI1988/3-2Deutsche Forschungsgemeinschaft KI1988/7-1
6 · The paper itself

Abstract

Chaperones safeguard protein homeostasis by promoting folding and preventing aggregation. HSP110 is a cytosolic chaperone that functions as a nucleotide exchange factor for the HSP70 cycle. Together with HSP70 and a J-domain protein (JDP), HSP110 maintains protein folding and resolubilizes aggregates. Interestingly, HSP110 is vital for the HSP70/110/JDP-mediated disaggregation of amyloidogenic proteins implicated in neurodegenerative diseases (i.e., α-synuclein, HTT, and tau). However, despite its abundance, HSP110 remains still an enigmatic chaperone, and its functional spectrum is not very well understood. Of note, the disaggregation activity of neurodegenerative disease-associated amyloid fibrils showed both beneficial and detrimental outcomes in vivo. To gain a more comprehensive understanding of the chaperone HSP110 in vivo, we analyzed its role in neuronal proteostasis and neurodegeneration in C. elegans. Specifically, we investigated the role of HSP110 in the regulation of amyloid beta peptide (Aβ) aggregation using an established Aβ-C. elegans model that mimics Alzheimer's disease pathology. We generated a novel C. elegans model that over-expresses hsp-110 pan-neuronally, and we also depleted hsp-110 by RNAi-mediated knockdown. We assessed Aβ aggregation in vivo and in situ by fluorescence lifetime imaging. We found that hsp-110 over-expression exacerbated Aβ aggregation and appeared to reduce the conformational variability of the Aβ aggregates, whereas hsp-110 depletion reduced aggregation more significantly in the IL2 neurons, which marked the onset of Aβ aggregation. HSP-110 also plays a central role in growth and fertility as its over-expression compromises nematode physiology. In addition, we found that HSP-110 modulation affects the autophagy pathway. While hsp-110 over-expression impairs the autophagic flux, a depletion enhances it. Thus, HSP-110 regulates multiple nodes of the proteostasis network to control amyloid protein aggregation, disaggregation, and autophagic clearance.

Indexed as

Amyloid beta-PeptidesCaenorhabditis elegansHSP110 Heat-Shock ProteinsAnimalsAnimals, Genetically ModifiedCaenorhabditis elegans ProteinsProtein AggregatesProtein Aggregation, PathologicalProteostasisAmyloid beta-PeptidesCaenorhabditis elegans ProteinsHSP110 Heat-Shock ProteinsProtein AggregatesAbetaaggregationC. eleganschaperonesproteostasis

Identifiers

PMID39180255
PMCPMC11657929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.